Compare Globus Medical Inc. Class A Common Stock (GMED) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.7 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 16.4× Globus Medical Inc. Class A Common Stock's market cap, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Vanguard Emerging Markets Stock Index Fund ETF for 135 Days on average.
| GMED | VWO | |
|---|---|---|
Market Cap | $10.25B | $168.50B |
Volume | 1,108,124 | 5,873,453 |
Sector | Health | — |
52-Week High | $96.82 | $61.44 |
52-Week Low | $58.33 | $52.42 |
Typical Hold Time | 0 Days | 135 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
VWO trades at $59.68, down slightly by 0.08% today. Technical indicators show a neutral overall signal with bearish moving averages, while RSI readings are neutral. The ETF focuses on emerging markets, with exposure to Taiwan's AI and semiconductor sectors but faces headwinds from China's economic slowdown. Recent news highlights institutional buying interest, such as Allianz increasing its stake by 12.6% in Q3 2026.
Outlook is mixed: AI-driven growth in Taiwan offers upside, but China's weakness and concentration risks pose challenges. The ETF's low expense ratio of 0.06% appeals for cost-conscious investors, yet emerging market volatility requires caution. Key risks include regional economic instability and currency fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
